Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

Ironwood Pharma (IRWD) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus

February 13, 2020 7:18 AM EST

Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.30, $0.06 better than the analyst estimate of $0.24. Revenue for the quarter came in at $126.3 million versus the consensus estimate of $111.85 million.

2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing... More